Ondine Biomedical Inc. (AIM:OBI)

Market Cap	39.89M
Revenue (ttm)	944.68K
Net Income (ttm)	-8.25M
Shares Out	443.23M
EPS (ttm)	-0.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,063
Average Volume	107,202
Open	8.50
Previous Close	8.80
Day's Range	8.50 - 9.00
52-Week Range	5.50 - 13.30
Beta	0.14
RSI	34.30
Earnings Date	May 9, 2025

About Ondine Biomedical

Ondine Biomedical Inc., a life-sciences company, engages in the development and commercialization of antimicrobial therapies in Canada and internationally. Its product platform is Photodisinfection, a light-based antimicrobial technology that provides destruction of pathogens without causing antibiotic resistance. The company’s lead product is Steriwave, a nasal photodisinfection solutions that destroys bacteria, viruses, and fungi colonizing the nose which leads to healthcare-associated infections. Its product pipeline also includes the develo...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 18
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: OBI

Financial Performance

In 2023, Ondine Biomedical's revenue was 1.20 million, an increase of 88.56% compared to the previous year's 638,000. Losses were -14.41 million, -25.60% less than in 2022.

Financial numbers in CAD